Depression trials recruiting in Georgia

All Depression trials nationally

Cities in Georgia

Recruiting trials in Georgia

• A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
  NCT07115329 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · Georgia: Stone Mountain
• A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
  NCT07592689 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Georgia: Atlanta, Decatur, Savannah
• A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
  NCT03887715 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta, Augusta, Decatur, Grayson
• A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
  NCT07172516 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Georgia: Atlanta, Decatur, Stone Mountain
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
  NCT06775379 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Georgia: Atlanta, Decatur, Marietta, Savannah
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
  NCT07076407 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Georgia: Atlanta
• A Study of Brenipatide in Adult Participants With Major Depressive Disorder
  NCT07412756 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Georgia: Decatur
• A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
  NCT07573176 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Georgia: Atlanta, Snellville
• A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
  NCT06793397 · Phase: Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · Georgia: Atlanta, Marietta
• A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
  NCT06696755 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Georgia: Atlanta
• A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
  NCT04777357 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · Georgia: Atlanta, Decatur, Dunwoody, Stockbridge
• A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
  NCT07276997 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Georgia: Atlanta, Norcross
• A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
  NCT06524830 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Georgia: Decatur, Savannah
• A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
  NCT07621237 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Norcross
• A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
  NCT07610473 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Georgia: Decatur
• A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
  NCT07300969 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Georgia: Atlanta, Decatur
• A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
  NCT07105111 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Augusta, Marietta
• A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
  NCT07227454 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · Georgia: Atlanta
• A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
  NCT07065240 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Georgia: Atlanta, Decatur, Marietta
• A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
  NCT06223880 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Georgia: Atlanta
• ALTO-100 in Bipolar Disorder With Depression (BD-D)
  NCT06656416 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Georgia: Atlanta, Peachtree Corners
• ALTO-207 in Adults With Treatment-resistant Depression (TRD)
  NCT07553637 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Georgia: Albany, Atlanta, Peachtree Corners, Savannah
• Assessing Improvements in Mood and Sleep Trial
  NCT06639477 · Phase: Not applicable (e.g. observational or device study) · Ages: 55 Years and older · Sex: All (male and female) · Georgia: Augusta
• Brain Stimulation and Decision-making
  NCT04099056 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 50 Years · Sex: All (male and female) · Georgia: Atlanta
• Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
  NCT07484217 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Georgia: Atlanta, Norcross, Snellville
• Dopaminergic Therapy for Anhedonia - 2
  NCT06075771 · Phase: Phase 4 · Ages: 25 Years to 55 Years · Sex: All (male and female) · Georgia: Atlanta
• E-Mindfulness Approaches for Living After Breast Cancer
  NCT06748222 · Phase: Phase 3 · Ages: 18 Years to 50 Years · Sex: All (male and female) · Georgia: Atlanta, Decatur, Johns Creek
• Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
  NCT05327699 · Phase: Early Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Georgia: Atlanta
• Inflammation and Depression in People With HIV
  NCT05849038 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Georgia: Atlanta
• JAK Signaling in Depression
  NCT07003997 · Phase: Phase 2 · Ages: 25 Years to 55 Years · Sex: All (male and female) · Georgia: Atlanta
• Leucine in Midlife Depression
  NCT06580145 · Phase: Phase 2 · Ages: 35 Years to 65 Years · Sex: All (male and female) · Georgia: Atlanta
• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06966401 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta
• Mechanisms of Behavioral Activation (BA)
  NCT05548244 · Phase: Not applicable (e.g. observational or device study) · Ages: 15 Years to 17 Years · Sex: All (male and female) · Georgia: Atlanta
• Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
  NCT06372964 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · Georgia: Atlanta, Lawrenceville, Savannah
• Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
  NCT07494305 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Georgia: Atlanta, Decatur
• NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06911112 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta
• PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
  NCT06713616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta
• Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
  NCT06559306 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Georgia: Atlanta, Decatur, Dunwoody, Savannah
• RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
  NCT07002034 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Georgia: Atlanta
• REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool
  NCT07280065 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Savannah
• Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
  NCT06633016 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Georgia: Atlanta, Decatur, Peachtree Corners, Savannah
• Study of ALTO-300 in MDD
  NCT05922878 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Georgia: Savannah, Snellville
• Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
  NCT05850689 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Georgia: Atlanta, Decatur
• Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
  NCT02604277 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 64 Years · Sex: All (male and female) · Georgia: Atlanta
• The OBSERVE Protocol
  NCT06725277 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Georgia: Atlanta
• Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
  NCT06423430 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years to 70 Years · Sex: All (male and female) · Georgia: Atlanta
• Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
  NCT06547489 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · Georgia: Savannah